Company Overview and News

 
BDB gets nine retailers for Jitra hub

2018-04-17 thestar.com.my
MOU-signing between BDB Land Sdn Bhd and EM Opulence Sdn Bhd on the lease of land for the operation of Petron petrol station at the Axis Commercial Hub signing ceremony. From left: BDB Acting Head of Group Property Division Mohd Iskandar Dzulkarnain, BDB Land Director Fakhruzi Ahmad, BDB Chairman Dato' Paduka Rasli Basir, EM Opulence Sdn Bhd Director Mohamad Zaini Yahya and Petron Development Manager of North/East Region Ravichandran Govindasamy.

 
BDB activates committee

2018-03-14 thestar.com.my
PETALING JAYA: Following the demise of Kedah-based property and construction firm Bina Darulaman Bhd ’s (BDB) managing direction Datuk Izham Yusoff on March 13, the board of directors of BDB are activating a business continuity management (BCM) committee.

 
Bina Darulaman MD Datuk Izham Yusoff passes away

2018-03-13 thestar.com.my
KUALA LUMPUR: Kedah-based property and construction firm Bina Darulaman Bhd (BDB) group managing director Datuk Izham Yusoff has passed away this morning, the company’s board of directors announced on its website. He was 50 years of age. According to the company’s annual report, Izham was appointed director of BDB on August 19, 2013 and subsequently re-designated to non-independent executive director and group MD February 1, 2014.

 
Despite financial losses, Bina Darulaman remains positive on future prospects

2018-02-21 themalaymailonline
Image from Bina Darulaman Bhd's online portal www.bdb.com.my.KUALA LUMPUR, Feb 21 — Bina Darulaman Bhd is optimistic of better prospects in the coming financial year despite recording losses in the fourth-quarter that ended on December 31 last year.

 
Report: Bina Darulaman sinks RM7.81m in FY17

2018-02-20 themalaymailonline
Bina Darulaman announced today that it posted net losses of RM7.81 million in financial year 2017 compared with earnings of RM34 million a year ago. — AFP picKUALA LUMPUR, Feb 20 — Bina Darulaman Berhad recorded losses in the fourth-quarter that ended on Dec 31 last year and dragged the full year into the red

 
 
Rasli stays on as BDB chairman

2017-12-29 thestar.com.my
KUALA LUMPUR: Bina Darulaman Bhd (BDB) has extended the contract of Datuk Paduka Rasli Basir as its non-executive chairman with effect from Jan 1, 2018.

 
1
BDB secures irrigation contract

2017-10-03 thestar.com.my
KUALA LUMPUR: Bina Darulaman Bhd (BDB) has secured a contract from the Agriculture and Agro-based Industry Ministry to develop an irrigation system worth RM18.21mil.

 
Breakfast briefing: Friday, July 21

2017-07-21 thestar.com.my
MarketWatch: Stocks ended little changed on Wall Street on Thursday as a deal between Sears and Amazon weighed on home improvement retailers while gains in Microsoft helped buoy the Nasdaq. The DJIA fell 28.97 points, or 0.13%, to close at 21,611.78, the S&P 500 lost 0.38 point, or 0.02%, to 2,473.45 and the Nasdaq added 4.96 points, or 0.08%, to 6,390.00. - Reuters

 
Bina Darulaman issues RM50m Sukuk Wakalah

2017-06-23 themalaymailonline
KUALA LUMPUR, June 23 — Bina Darulaman Bhd (BDB) has issued its maiden RM50 million Sukuk Wakalah, the first tranche of its seven-year RM100 million Sukuk Wakalah Programme.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...